

AMENDMENTS

Listing of Claims:

The following listing of claims replaces all previous listings or versions thereof:

1. (Currently amended) An attenuated vaccinia virus comprising a first ~~and a second~~ mutation, wherein the first mutation is in a B18R first gene encoding an interferon-modulating polypeptide that results in the virus lacking at least a first functional interferon-modulating polypeptide, wherein ~~wherein the first interferon-binding polypeptide is B18R~~ the virus is a Copenhagen or Western Reserve strain of vaccinia virus.
2. (Canceled)
3. (Previously presented) The attenuated vaccinia virus of claim 9, wherein the second interferon-binding polypeptide is B8R.
4. – 5. (Canceled)
6. (Currently amended) The attenuated vaccinia virus of claim 1, ~~wherein the further~~ comprising a second mutation in at least one of the following:
 - (a) a second gene encoding an interferon-modulating polypeptide that results in the virus lacking at least a second functional interferon-modulating polypeptide;
 - (b) a gene encoding a complement control polypeptide, wherein the mutation results in the virus lacking at least one functional complement control polypeptide;
 - (c) a gene encoding a TNF-modulating polypeptide, wherein the mutation results in the virus lacking at least one functional TNF-modulating polypeptide;
 - (d) a gene encoding a serine protease inhibitor, wherein the mutation results in the virus lacking at least one functional serine protease inhibitor;
 - (e) a gene encoding an IL-1 β modulator polypeptide, wherein the mutation results in the virus lacking at least one functional IL-1 β modulator polypeptide;

- (f) a gene encoding a functional A41L, B7R, N1L or vCKBP chemokine binding polypeptide or C11R EGF-like polypeptide, wherein the mutation results in the virus lacking at least one function of A41L, B7R, N1L, vCKBP, or C11R; or
- (g) a gene encoding a polypeptide, wherein the mutation results in an increase in infectious EEV form of vaccinia virus.

7.-8. (Canceled)

9. (Original) The attenuated vaccinia virus of claim 6, comprising the mutation in a gene encoding a second interferon-modulating polypeptide that results in the virus lacking at least a second functional second interferon-modulating polypeptide.

10. - 19. (Canceled)

20. (Withdrawn) The attenuated vaccinia virus of claim 1, comprising the mutation in a gene encoding a complement control polypeptide that results in the virus lacking at least one functional complement control polypeptide.

21. (Canceled)

22. (Withdrawn) The attenuated vaccinia virus of claim 6, comprising the mutation in a gene encoding a TNF-modulating polypeptide that results in the virus lacking at least one functional TNF-modulating polypeptide.

23. (Canceled)

24. (Withdrawn) The attenuated vaccinia virus of claim 6, comprising the mutation in a gene encoding a serine protease inhibitor that results in the virus lacking at least one functional serine protease inhibitor.

25. (Canceled)

26. (Withdrawn) The attenuated vaccinia virus of claim 6, comprising the mutation in a gene encoding an IL-1 β modulator that results in the virus lacking at least one functional IL-1 β modulator.

27. (Withdrawn) The attenuated vaccinia virus of claim 26, wherein the functional IL-1 β modulating polypeptide is B13R or B15R.

28. (Withdrawn) The attenuated vaccinia virus of claim 6 comprising a mutation in a gene encoding a functional A41L, B7R, N1L or vCKBP chemokine binding polypeptide or C11R EGF-like polypeptide.

29. – 30. (Canceled)

31. (Withdrawn) The attenuated vaccinia virus of claim 6, comprising the mutation that results in an increase in production of infectious EEV form of vaccinia virus.

32. - 34 (Canceled)

35. (Withdrawn , Currently amended) The attenuated vaccinia virus of claim 6, wherein the virus comprises ~~more~~ at least two different mutations in (a), (b), (c), (d), (e), (f) or (g).

36. (Withdrawn) The attenuated vaccinia virus of claim 35, wherein the virus comprises a mutation in (g) and at least a mutation in (a), (b), (c), (d), (e) or (f).

37. (Original) The attenuated vaccinia virus of claim 1, wherein the virus is comprised in a pharmaceutical composition.

38. – 120. (Canceled)

121. (Previously presented) The attenuated vaccinia virus of claim 1, further comprising a thymidine kinase mutation that results in a non-functional thymidine kinase (TK⁻).

122. (Previously presented) The attenuated vaccinia virus of claim 121, wherein the thymidine kinase mutation is a point mutation.

123. (Previously presented) The attenuated vaccinia virus of claim 122, wherein the thymidine kinase mutation is a deletion.